ITGAE (Integrin alpha-E/CD103) Drug Discovery Landscape & Assay Solutions
- By admin
- 03 Sep 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ITGAE drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ITGAE/ITGB7 Heterodimer Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View ITGAE Products |
| Gene Delivery | ITGAE Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based assays. |
View ITGAE Products |
| Benchmark Ab | Anti-ITGAE Recombinant Antibody Recombinant positive control derived from clinical benchmark clones. |
View ITGAE Products |
| Validator | ITGAE siRNA Set For target knockdown and specificity verification. |
View ITGAE Products |
| Related Target A | ITGB7 (Integrin beta-7) Essential heterodimerization partner required for functional CD103 expression. |
View ITGB7 Products |
| Related Target B | CDH1 (E-Cadherin) Primary physiological ligand of the ITGAE/ITGB7 complex. |
View CDH1 Products |
| Related Target C | TGFB1 (TGF-beta 1) Key cytokine driving ITGAE upregulation in tissue-resident memory T cells. |
View TGFB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation-dependent binding (ITGAE/ITGB7 heterodimer) | Co-expressed recombinant heterodimers with native glycosylation (HEK293) and theoretical MW verification. |
| Cross-species ortholog screening (Cyno/Mouse) | Human, Mouse, and Cynomolgus ITGAE ortholog proteins available with >95% purity. |
| Lack of clinical-grade positive controls | Sequence-verified recombinant benchmark antibodies included in the catalog. |
| Off-target integrin cross-reactivity (e.g., ITGA4) | Counter-screening panel proteins strictly verified by mass spectrometry. |
Live ITGAE R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ITGAE (CD103) therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to bispecific antibodies and targeted cell depletion therapies. CD103 is highly expressed on tissue-resident memory T cells (TRM) and intraepithelial lymphocytes, making it a critical node in both mucosal immunity and tumor microenvironment modulation. As first-generation therapies targeting the broader integrin beta-7 pathway reach the clinic, the next wave of R&D is targeting highly specific CD103 heterodimers to avoid systemic immunosuppression and achieve localized therapeutic efficacy in solid tumors and inflammatory bowel diseases (IBD).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific Antibody (e.g., CD103 x PD-L1) | Roche, Biotech Consortia | Solid Tumors (NSCLC, Ovarian) | Simultaneous binding assays (Need high-purity CD103/ITGB7 heterodimer) |
| Monoclonal Antibody (Blocking) | Takeda, Genentech | Inflammatory Bowel Disease (IBD) | E-Cadherin competitive blocking assays (Need CDH1 and ITGAE proteins) |
| Antibody-Drug Conjugate (ADC) | Academic Medical Centers | Hairy Cell Leukemia, T-cell Lymphoma | Internalization validation (Need stable cell lines via Lentivirus) |